B · Normal
[Innovative drugs and CRO concepts are active, and Jinling Pharmaceutical is at daily limit] November 4th, innovative drugs and CRO concepts are active, Jinling Pharmaceutical is at daily limit, nearshore protein is up over 7%, BeiGene, Yifang Biologics, Wanbang Pharmaceuticals, and WuXi AppTec are following suit. According to the news, on November 2, Germany’s Fresenius and WuXi Biologics signed an exclusive development agreement. Fresenius has the exclusive right to choose up to 37 potential first batch biosimilar drug candidate products. The company said this is the largest development agreement announced to date in the biosimilar industry.
Live broadcast 🕐 2026-11-04 09:48
#Live broadcast #CRO
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Analysis of the midday limit on November 4th] On November 4th, at noon today, a 11-04 11:59 [Afternoon Commentary: The GEM index rose higher and fell slightly, and robots a 11-04 11:32 [Main Fund Monitoring: Zhongji InnoLight’s net sales exceeded 700 million] Novem 11-04 10:54 [The concept of ice and snow economy rebounded in shock, Bingshan Cold and Hot h 11-04 10:29 [The concept of humanoid robots continues to rise, and many stocks such as Jack 11-04 10:25 [The concept of device-side AI fluctuated higher, Longxun Technology Co., Ltd. a 11-04 10:15

Comments

0/500
Captcha (click to refresh)
No comments yet